FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The complaint called the FDA's decision to restrict the compounding of tirzepatide "a reckless and arbitrary decision [...] to deprive patients of a vital treatment for type 2 diabetes and obesity."The U.S. Food and Drug Administration (FDA) is reassessing a decision to ban compounding pharmacies to supply cheaper versions of Eli Lilly And Co's (NYSE:LLY) blockbuster weight loss and diabetes drugs.
美国食品药品监督管理局（FDA）正在重新评估一项决定，即禁止复方药房提供更便宜的礼来公司（纽约证券交易所代码：LLY）重磅减肥和糖尿病药物。
What Happened: Reuters highlighted how the FDA had banned compounding pharmacies to supply cheaper versions of the medication, but is now reconsidering that decision.
发生了什么：路透社强调了美国食品药品管理局是如何禁止复方药房提供更便宜的药物的，但现在正在重新考虑这一决定。
The compounding groups Outsourcing Facilities Association and FarmaKeio Custom Compounding had filed a complaint against the FDA for the deciaion but the lawsuit has since been put on hold.
复合组织外包设施协会和Farmakeio定制化合物已就该决定对美国食品药品管理局提出申诉，但该诉讼此后被搁置。
The complaint called the FDA's decision to restrict the compounding of tirzepatide "a reckless and arbitrary decision [...] to deprive patients of a vital treatment for type 2 diabetes and obesity."
该投诉称，美国食品药品管理局限制复方替西帕肽的决定 “是一个鲁莽而武断的决定 [...]，旨在剥夺患者治疗2型糖尿病和肥胖症的重要方法。”
Last week, Eli Lilly said it issued hundreds of cease-and-desist letters to telehealth companies, compounding pharmacies, and medical spas, demanding they halt the production, sale, and promotion of products that imitate its drugs, Mounjaro and Zepbound.
上周，礼来公司表示，它向远程医疗公司、复合药房和医疗水疗中心发出了数百封停止和终止信，要求他们停止生产、销售和推广模仿其药物的产品Mounjaro和Zepbound。
The tirzepatide injection, branded as Mounjaro and Zepbound, has been in shortage since 2022.
自2022年以来，名为Mounjaro和Zepbound的替塞帕肽注射剂一直处于短缺状态。
Price Action: Lilly stock closed at $931.74 on Friday
价格走势：礼来股票周五收于931.74美元
- Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names.
- 尽管可能有16种新的肥胖药物占据市场主导地位，但诺和诺德、礼来公司仍可能面临下行压力：见名字。
